贝图林酸载荷的油凝作为潜在皮肤应用的新型药物配方:开发,表征和生物安全性概况
Andreea Smeu1,2, Daliana Minda3, Casiana Boru4
1Research Centre for Pharmaco-Toxicological Evaluation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Life (Basel, Switzerland)
|June 26, 2025
概括
这项研究开发了一种用于治疗皮肤疾病的酸 (BA) 油凝. 该配方显示出出色的安全性和生物相容性,表明了局部皮肤治疗的潜力.
科学领域:
- 皮肤病学和制药科学 皮肤病学和制药科学
- 生物材料和药物输送
背景情况:
- 皮肤疾病很普遍,需要有效的局部治疗.
- 贝图林酸 (BA) 是一种三烯,在皮肤疾病中具有治疗潜力,但其生物利用性不佳.
- 油脂为像BA这样的疏水化合物提供了一个有前途的输送系统,但它们在BA输送方面的应用尚未得到充分探索.
研究的目的:
- 开发和表征一种含有贝鲁林酸的油脂凝 (BA-O),用于局部施用.
- 评估开发的BA-O配方的皮肤安全性和生物相容性.
主要方法:
- 将贝鲁丁酸 (BA) 制成一个油凝系统 (BA-O).
- BA-O局部配方的物理化学表征.
- 在体外细胞毒性评估使用HaCaT和JB6 Cl 41-5a皮肤细胞.
- 在卵子安全性评估使用EpiDermTM组织和chorioallantoic膜测定.
主要成果:
- 该BA-O配方符合局部半固体配方的物理化学标准.
- BA-O显示出高生物相容性,在皮肤细胞系中没有观察到细胞毒性作用 (活力>70%).
- 该配方在皮肤组织模型 (EpiDermTM活力> 80%) 和胆膜 (刺激评分 = 0.186) 中被归类为非刺激性.
结论:
- 贝图林酸可以有效地被纳入油脂凝中,用于局部应用.
- 开发的BA-O具有良好的临床前生物安全性,具有较低的细胞毒性和非刺激性.
- 在皮肤皮肤病学应用中,BA-O具有未来研究的前景潜力.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
360
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
360
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336